In these specific subtypes of cervical cancer, patients with a KRAS mutation had a worse prognosis.47 Additionally, Wright and co-authors indicated that out of 40 patients with adenocarcinoma, 8.8% presented with KRAS mutations which were not detected in patients with SCC.48 These KRAS mutations were typical G12 and G13 missense mutations within the guanine exchange factor domain. The gene discussed is KRAS; the disease is cervical cancer.